🇺🇸 FDA
Patent

US 12247226

Cellular reprogramming using temporal and transient plasmid vector expression system

granted A61KA61K35/12

Quick answer

US patent 12247226 (Cellular reprogramming using temporal and transient plasmid vector expression system) held by Fate Therapeutics, Inc. expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Fate Therapeutics, Inc.
Grant date
Tue Mar 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
39
CPC classes
A61K, A61K35/12